Glenmark Pharmaceuticals Limited — Updates, 16-12-2024: Press Release

Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Oral Solution, 10 mg/mL, which is bioequivalent to UCB, Inc.'s Vimpat® Oral Solution, 10 mg/mL. The annual market for Vimpat® Oral Solution reached approximately $57 million according to IQVIA sales data for the year ending October 2024. This launch reinforces Glenmark’s commitment to providing quality and affordable alternatives for patients in the market.

Glenmark's product portfolio currently consists of 201 products authorized for distribution in the U.S., with 51 ANDAs pending approval. The company is also actively pursuing external development partnerships to enhance its pipeline and growth prospects. Investors should view this product launch positively, as it not only expands Glenmark's offerings but also positions the company to capitalize on a lucrative segment of the market, suggesting potential future growth and revenue streams.